drugset / Trial / NCT06872333
Allo HSCT for High Risk Hemoglobinopathies
Non-randomizedParallel-groupOpen-labelOther
Summary
A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.
Timeline
- Start
- 2024-11-19
- Primary completion
- 2030-06-01
- Completion
- 2032-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alemtuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Busulfan | Small molecule | — | — |
| Subject | Cyclophosphamide | Other / unclassified | 14.5 mg/kg | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 50 mg/kg | Intravenous |
| Subject | Fludarabine | Small molecule | 20 mg/ml | Intravenous |
| Subject | Mycophenolate Mofetil | Small molecule | 15 mg/kg | — |
| Subject | Plerixafor | Small molecule | — | — |
| Subject | Sirolimus | Small molecule | — | — |
| Subject | Tacrolimus | Small molecule | — | — |
| Subject | Thymoglobulin | Protein / enzyme biologic | — | Intravenous |